Address: |
333 University Av., Suite 120 |
Education and Employment History: |
|
Relevant Experience: |
|
Procedure Skills: |
|
License/Certification: |
|
Publications: |
|
Clinical Trial Participation: |
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Center Trial Evaluating the Efficacy and Safety of XXX in Adult Patients on Chronic Hemodialysis. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Phase III, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients previously treated with Epogen. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Phase IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Phase II, Randomized, Double-Blind Placebo-Controlled, Multi-Center, to Evaluate the Safety and Efficacy of XXX in Patients with Nephropathy Due to Type 2 Diabetes. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators Patient FOCUS Group for Qualitative Assessment of Anemia Associated with Chronic Kidney Disease. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of XXX in Patients with Type 2 Diabetes Mellitus and End Stage Renal Disease who are on Dialysis and who have Inadequate Glycemic Control. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Phase II Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure on Hemodialysis, or Do Not Require Dialysis and Previously Treated with Darbepoetin Alfa. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of XXX to Licensed Vaccine (Energix-B®) among Adults (18-75 years of age) with Chronic Kidney Disease (CKD). Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Randomized Evaluation of Efficacy and Safety of XXX in Patients with Iron Deficiency Anemia and Impaired Renal Function. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Phase 2, Multicenter, Randomized, Double-Blind Study of the Safety, Clinical Activity and Pharmacokinetics of XXX Versus Placebo in Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD). Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a XXX in Adults with Type 2 Diabetes and Overt Nephropathy. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX in Patients with Systemic Lupus Erythematosus (SLE). Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators A Phase IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX. Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators Observational Study in Patients with Chronic Kidney Disease and Type 2 Diabetes: Identifying Patients: Identifying Patients with Estimated GFR Between 15 and 30 mL/min/1.73m². Naveen Atray, MD as PI; Mezger, MD, Gelfand, MD, Nallamothu, MD as sub-investigators March 2011: QWC01-MN-01 – A Randomized, Placebo-Controlled, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome due to Idiopathic Membranous Nephropathy (iMN) May 2011: 402-C-0903 – Bardoxolone Methyl Evaluation in patients with Chronic Kidney Disease and Type 2 Diabetes; The Occurrence of Renal Events (BEACON) August 2011: AFX01-18 – A Phase 3b Single-Arm, Conversion Study from Epoetin alfa to Monthly Peginesatide Injection in Patients with Chronic Kidney Disease on Dialysis. August 2011: EPOE-10-13 – A Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Subcutaneous Epoetin Hospera and Epoetin Alfa (Amgen) in Patients with Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. July 2012: ISG2012 – An Open Label Equivalence Study Comparing 50mg Weekly to 100mg Biweekly Maintenance Intravenous Iron Sucrose to Assess Impact in Ferritin, Transferrin Saturation, and Hemoglobin in Hemodialysis Patients October 2012: CTAP101-CL-3001 – A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects with Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency December 2012: ZS -003 – A Phase 3 Multicenter, Two-Phase, Multi-Dose, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia January 2013: RLY5016-301 – A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia May 2013: D5610C00001 – An Exploratory Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of ASD1722 in CKD patients with Type 2 Diabetes Mellitus and Albuminuria May 2013: M11-352 – A Randomized, Multcountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Study of Diabetic Nephropathy and Atrasentan May 2013: KRX-0502-204 – A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects with Stage III to V Chronic Kidney Disease Not on Dialysis July 2013: CTAP101-CL-3003 - A Long-term Safety and Efficacy study of CTAP101 Capsules in Subjects with Stages 3 or 4 Chronic Kidney Disease Secondary Hyperparathyroidism and Vitamin D insufficiency (Extension Study CTAP101-CL-3001) July 2013: MK-3102-019 - A Phase III, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects with Type 2 Diabetes Mellitus with Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control August 2013: AKB-6548-CI-0007 – Phase 2b randomized, double-blind, placebo-controlled study to assess the Pharmacodynamic response, safety, and tolerability to 20 weeks of oral dosing of AKB-6548 in subjects with anemia secondary to chronic kidney disease (CKD), GFR categories G3A-G5 (Stages 3, 4 and 5) (Pre-dialysis) October 2013: AMAG-FER-CKD-401: Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis June 2014: VPI-CLN-201-AD: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI-2690B Injection in Patients With Nephropathy Due to Diabetes June 2014: D5613C00001 A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre Dose finding Study to evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis June 2014: 28431754DNE3001-Phase 3 Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy August 2014: ZS-005 - A Phase 3 Multicenter, Multi-dose, Open-label Maintenance Study to Investigate the Long-term Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), an Oral Sorbent, in Subjects With Hyperkalemia, Including a Randomized, Double-blind, Placebo-controlled, Withdrawal Study September 2014: KRX-0502-306 - A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia in Adult Subjects with Non-Dialysis Dependent Chronic Kidney Disease April 2015: D5740C00001 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis June 2015: D5740C00002 - A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients |
Capital Nephrology Medical Group
333 University Av., Suite 120
Sacramento, CA 95825
Tel: 916-929-8564
Fax: 916-929-4529
View Office Locations in a larger map